Resource Centers
Pharma Dev & Mfg
Videos
ICON- Partnerships 12
Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON collects images in a variety of trials, particularly in the areas of oncology and cardiovascular trials. In their partnership with Roche, ICON hosts the database containing all of the images they collect for all of Roche's clinical trials. This allows Roche to view any of their images 24/7 via ICON's hosting cloud software - saving Roche the significant investment required for an imaging system and the time it would take to traditionally deliver images to the sponsor. ICON provides yet another example of how they are helping their partners deliver more drugs to market in a faster and more cost effective way.
Make sure you enter the (*) required information where indicated. HTML code is not allowed.
Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.